Klivira
Request demo

Streamlining Humana Xtandi Prior Authorization Workflows

Navigating Humana Xtandi prior authorization requires a precise understanding of payer-specific channels and policy nuances. Klivira automates critical steps to accelerate approvals for this high-volume specialty medication.

For revenue cycle directors and prior authorization teams, managing specialty drug PAs, particularly for high-volume medications like Xtandi, presents significant operational challenges. Understanding Humana's specific requirements, submission pathways, and policy criteria is paramount for minimizing denials and ensuring timely patient access.

Xtandi (Enzalutamide): A High-Volume Prior Authorization Target

Xtandi, an androgen receptor inhibitor (enzalutamide), is a critical medication used in the treatment of prostate cancer. Due to its high cost and specific indication, it is consistently identified as a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans. Efficient PA processing for Xtandi directly impacts patient care pathways and revenue integrity.

Humana's Prior Authorization Channels for Xtandi

Humana, a major Medicare Advantage carrier, utilizes distinct channels for prior authorization submissions. For medical benefit Xtandi, providers typically initiate PAs through Availity Essentials, which serves as Humana's primary provider portal for many workflows. X12 278 transactions are also supported via clearinghouses. For pharmacy benefit Xtandi, submissions route through Humana's pharmacy benefit operation, often via CenterWell Pharmacy or CenterWell Specialty Pharmacy, and leverage ePA platforms like CoverMyMeds or Surescripts for prescriber-initiated workflows.

Accessing Humana's Utilization Management Policies for Xtandi

  • Humana publishes medical-policy and coverage-determination documents on its provider site, which should be referenced by specific policy or coverage-determination number and effective date.
  • For Medicare Advantage lines, Humana's coverage policies must align with CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for the applicable Medicare jurisdictions.
  • Humana medical policies often disclose whether criteria are Humana-developed, MCG-based, NCCN-compendium-based (for oncology, relevant to Xtandi), or sourced from partner vendors.
  • Medicare Advantage plans cannot impose prior authorization criteria more restrictive than Original Medicare's coverage rules for the same service, a key consideration for Xtandi PA.

Electronic Prior Authorization (ePA) and Humana's Da Vinci Posture

Humana is an active participant in the HL7 Da Vinci Project ecosystem, indicating a strategic move towards standardized electronic prior authorization (ePA) via FHIR-based APIs. While specific Da Vinci PAS, CRD, and DTR conformance status requires verification, this aligns with broader industry trends towards API-driven PA. For pharmacy benefit Xtandi, existing ePA pathways through CoverMyMeds and Surescripts remain critical for prescriber-initiated workflows, complementing medical-benefit ePA developments.

Understanding Humana's PA Turnaround Times and CMS-0057-F Impact

Humana publishes precertification turnaround commitments on its provider site. For its significant Medicare Advantage enrollment, statutory timeframes apply: historically 14 calendar days for standard pre-service decisions and 72 hours for expedited. The CMS-0057-F rule further tightens these for impacted payers like Humana to 7 calendar days for standard PA and 72 hours for expedited, with phased compliance through 2027 for electronic PA API conformance. These regulatory shifts necessitate robust automation for efficient processing.

Common Denial Reasons and Appeal Pathways for Xtandi with Humana

Denials for specialty drugs like Xtandi from Humana are typically returned via X12 277/835 or portal status updates. Common reasons include medical necessity/insufficient documentation, NCD/LCD non-coverage for MA lines, and step therapy requirements not met or documented. Humana documents its appeal pathway in its provider manual and on the provider site, with Medicare Advantage appeals following the CMS-mandated 5-level structure for organization determinations. Peer-to-peer reviews and expedited appeals are available options.

Frequently asked questions

How do I submit a prior authorization for Xtandi to Humana?

For medical benefit Xtandi, prior authorizations are typically submitted through Humana's dedicated portal on Availity Essentials. For pharmacy benefit Xtandi, submissions often route through CenterWell Pharmacy or CenterWell Specialty Pharmacy, utilizing ePA platforms such as CoverMyMeds or Surescripts for prescriber-initiated requests. X12 278 transactions are also supported for medical benefit PAs.

Where can I find Humana's specific coverage criteria for Xtandi?

Humana publishes its medical-policy and coverage-determination documents on its provider website. When reviewing policies for Xtandi, ensure you reference the specific policy or coverage-determination number and effective date. For Medicare Advantage plans, these policies must also align with applicable CMS National and Local Coverage Determinations.

What are the typical turnaround times for Humana Xtandi prior authorizations?

Humana publishes its precertification turnaround commitments on its provider site. For Medicare Advantage lines, standard pre-service decisions are subject to statutory timeframes, which are being further tightened by CMS-0057-F to 7 calendar days for standard PA and 72 hours for expedited requests. These timeframes are critical for patient access.

What are common reasons for Humana to deny Xtandi prior authorizations?

Common denial reasons for specialty drugs like Xtandi under Humana include insufficient documentation to demonstrate medical necessity, non-compliance with NCD/LCD for Medicare Advantage, or failure to meet documented step therapy requirements. It is crucial to provide comprehensive clinical records supporting the request and address any step therapy prerequisites.

Does Humana support electronic prior authorization (ePA) for Xtandi?

Yes, Humana participates in the HL7 Da Vinci Project, indicating a commitment to FHIR-based electronic prior authorization. For pharmacy benefit Xtandi, ePA is supported through established platforms like CoverMyMeds and Surescripts. Klivira integrates with these various channels to streamline electronic submissions where available.

Related coverage

Other xtandi prior authorization by payer

Other xtandi prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo